Deposition of islet amyloid pancreatic polypeptide (IAPP) in the islets of Langerhans is the characteristic feature of human type 2 diabetic pancreas but represents the final stage of a process started long before. Recent evidence suggests that ?-cell toxicity of amyloidogenic peptides results, not in the deposits visible by light microscopy, but rather from intracellular fibril aggregates and soluble oligomers that act as non-selective ion channels. Toxic IAPP fibrils and oligomers share a common structure with Alzheimer Disease (AD)-related ?-amyloid (A?) fibrils and oligomers, suggesting a similar pathogenesis of type 2 diabetes mellitus (T2DM) and AD. Moreover, pancreatic ?-cells express high levels of AD-related peptides, and T2DM is frequently associated with AD. Non human primates (NHPs) represent ideal models to study the role of amyloidogenic peptides in ?-cell decompensation, because NHPs spontaneously develop islet amyloidosis and T2DM very similarly to humans.
Our specific aims are: (1) to study ?-cell function, morphology, and ultrastructure in insulin sensitive (IS) and insulin resistant (IR) baboons;(2) to examine the effects of an acute increase in insulin secretory demand (achieved by partial pancreatectomy, PPx) on ?-cell function, morphology and ultrastructure (with particular emphasis on IAPP and A?) in normal glucose tolerant (NGT) IS and IR baboons;(3) to examine the effects of different therapeutic interventions aimed at preventing PPx-induced ?-cell decompensation;(4) to test the hypothesis that abnormal A? metabolism and glutamate transporter (GLT-1) activity may induce ?-cell death;(5) to study the molecular mechanisms responsible for IAPP- and A?-induced cytotoxicity in vivo in the baboon pancreas (prior and after PPx) and in vitro in ?-cells lines and isolated baboon islets. Particular emphasis will be placed in amyloidogenesis, and endoplasmic reticulum (ER) stress, insulin signaling (insulin receptor substrate-2, IRS-2) and degradation (insulin degrading enzyme, IDE), and glutamate transport (GLT- 1) and metabolism (production of ?-aminobutyric acid, GABA);(6) to study the molecular mechanisms responsible for the beneficial effect of Exenatide on ?-cell expansion/neogenesis and survival in vivo and in vitro with particular emphasis on IAPP- and A?-induced cytotoxicity and ER stress, insulin signaling and degradation, and glutamate transport and metabolism. Understanding the molecular mechanisms of amyloid deposition and ?-cell death in the baboon could provide the rationale for the novel therapeutic approaches.

Public Health Relevance

Our project is aimed at: 1) Clarifying the physiological and molecular mechanisms of adaptation to increased metabolic demand of insulin-producing pancreatic cell in a novel non-human primate model of obesity and type 2 diabetes, the baboon, and the effect of new therapies aimed at the protection of insulin producing cells, 2) clarifying the cellular and molecular mechanisms underlying abnormal protein deposition and cell death in insulin-producing pancreatic in baboon islets of Langerhans and beta cell lines and the effect of new therapies aimed at preventing this phenomenon. Given the extremely high genetic similarity of this non human primate to humans and the possibility to dissect novel molecular mechanisms of insulin producing cell death as well as the mechanisms by which some drugs could prevent it, these studies will allow us to discover new treatments to prevent the loss of insulin-producing pancreatic cells in patients affected by type 2 diabetes mellitus.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
1R01DK080148-01A2
Application #
7655613
Study Section
Cellular Aspects of Diabetes and Obesity Study Section (CADO)
Program Officer
Appel, Michael C
Project Start
2009-06-10
Project End
2011-05-31
Budget Start
2009-06-10
Budget End
2010-05-31
Support Year
1
Fiscal Year
2009
Total Cost
$454,662
Indirect Cost
Name
University of Texas Health Science Center San Antonio
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
800772162
City
San Antonio
State
TX
Country
United States
Zip Code
78229
Fiorentino, Teresa Vanessa; Owston, Michael; Abrahamian, Gregory et al. (2015) Chronic continuous exenatide infusion does not cause pancreatic inflammation and ductal hyperplasia in non-human primates. Am J Pathol 185:139-50
Guardado Mendoza, Rodolfo; Perego, Carla; Finzi, Giovanna et al. (2015) Delta cell death in the islet of Langerhans and the progression from normal glucose tolerance to type 2 diabetes in non-human primates (baboon, Papio hamadryas). Diabetologia 58:1814-26
Guardado-Mendoza, R; Jimenez-Ceja, L; Majluf-Cruz, A et al. (2013) Impact of obesity severity and duration on pancreatic ?- and ?-cell dynamics in normoglycemic non-human primates. Int J Obes (Lond) 37:1071-8
Quinn, Amy R; Blanco, Cynthia L; Perego, Carla et al. (2012) The ontogeny of the endocrine pancreas in the fetal/newborn baboon. J Endocrinol 214:289-99
Davalli, Alberto M; Perego, Carla; Folli, Franco B (2012) The potential role of glutamate in the current diabetes epidemic. Acta Diabetol 49:167-83
Westermark, Gunilla T; Davalli, Alberto M; Secchi, Antonio et al. (2012) Further evidence for amyloid deposition in clinical pancreatic islet grafts. Transplantation 93:219-23
Di Cairano, Eliana S; Davalli, Alberto M; Perego, Lucia et al. (2011) The glial glutamate transporter 1 (GLT1) is expressed by pancreatic beta-cells and prevents glutamate-induced beta-cell death. J Biol Chem 286:14007-18
Kamath, Subhash; Chavez, Alberto O; Gastaldelli, Amalia et al. (2011) Coordinated defects in hepatic long chain fatty acid metabolism and triglyceride accumulation contribute to insulin resistance in non-human primates. PLoS One 6:e27617
Folli, Franco; Guardado Mendoza, Rodolfo (2011) Potential use of exenatide for the treatment of obesity. Expert Opin Investig Drugs 20:1717-22